Avalon GloboCare Announces Issuance of Key U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules
Avalon GloboCare Corp. (NASDAQ: ALBT) announced the issuance of U.S. Patent No. 11,555,060 by the USPTO, covering the QTY Code, a breakthrough technology transforming water-insoluble proteins into soluble forms. This patent strengthens Avalon's intellectual property in immuno-oncology and cellular therapies, enhancing its competitive edge. The QTY platform has significant potential for applications, including addressing cytokine storms from COVID-19 and improving CAR T-cell therapies. Avalon has filed 16 joint patent applications with prestigious partners like MIT and aims to lead in innovative biotechnology solutions.
- Issuance of U.S. Patent No. 11,555,060 enhances Avalon’s intellectual property portfolio.
- QTY Code technology improves solubility of proteins, expanding therapeutic targets.
- Potential applications include treating cytokine storms and enhancing CAR T-cell therapies.
- None.
Patent Jointly Filed with the Massachusetts Institute of Technology (MIT)
FREEHOLD, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics and laboratory testing provider, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,555,060, titled “QTY Fc Fusion Water Soluble Receptor Proteins.” The issued claims cover the composition of matter and methodology for multiple novel QTY-code modified cytokine and chemokine protein receptor molecules. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT).
The “QTY Code,” is a breakthrough technology that can turn difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, greatly enhancing the solubility of designer peptides and proteins, therefore expanding the repertoire of selected therapeutic targets against cancers and other diseases.
“We are pleased to be granted this key patent by the USPTO which expands our intellectual property portfolio,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “We have jointly filed 16 patent applications, co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology, and this issuance further enhances our position as a leader in immuno-oncology and cellular medicines.”
“The QTY code protein design platform, which was developed together with Professor Shuguang Zhang’s laboratory at MIT, can turn water-insoluble proteins that normally reside within cellular membranes—and that can be difficult to work within the laboratory—into water-soluble proteins that can be potentially used in many clinical applications. The resulting soluble, antibody-like cytokine/chemokine decoy receptors derived using the QTY protein design, have many potential applications including mitigation of the “cytokine storm” associated with COVID-19 and cellular immunotherapy delivery, as well as broadening the range of therapeutic targets addressable by CAR T-cell therapies,” concluded Dr. Jin.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a clinical-stage biotechnology company dedicated to developing and delivering innovative, transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare’s developments, please follow our twitter at @avalongc_avco
Forward-Looking Statements
Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the potential transaction and financing and conditions to closing and the business of Laboratory Services. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com
FAQ
What is the significance of Avalon GloboCare's new patent issued on January 17, 2023?
How does the QTY Code technology impact Avalon GloboCare's business operations?
What are the potential applications of the QTY Code technology developed by Avalon and MIT?
What is Avalon GloboCare's stock symbol and listing?
When was the patent related to QTY Code issued to Avalon GloboCare?
